首页> 外文期刊>胸部外科 >Expression of telomerase activity in thymoma and thymiccarcinoma tissues; a clinicopathological study
【24h】

Expression of telomerase activity in thymoma and thymiccarcinoma tissues; a clinicopathological study

机译:端粒酶活性在胸腺瘤和胸腺癌组织中的表达; 临床病理学研究

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Telomerase is a nucleoprotein complex that caps the physical termini of all eukaryotic chromosomes. It is suggested that telomerase play important roles in unlimited cell division acquisition of the malignant phenotype. We studied the relation of telomerase activity in thymoma and thymic carcinoma to the clinicopathological features of these lesions. METHODS: Tissue specimens were surgically resected from patients with thymoma and thymic carcinoma. Telomerase activity was evaluated according to a modified telomeric repeat amplification protocol (TRAP) assay. RESULTS: Telomerase activity was detected in all thymic epithelial tumors. The activity (mean +/- SD: unit/microgram.protein) in thymoma (n = 17) was significantly higher than that in thymic carcinoma (n = 7) [431.8 +/- 400.1 vs. 68.8 +/- 39.8: p < 0.01]. Telomerase activities in thymoma and thymic carcinoma were significantly higher than that in primary lung adenocarcinoma (33.5 +/- 39.2: n = 47), studied as control (p < 0.01). In patients with thymoma, telomerase activity did not correlate with tumor stage according to Masaoka classification (p = 0.776). In patients with thymic carcinoma, however, telomerase activity positively correlated with tumor stage (p = 0.02). In thymoma, telomerase activity positively correlated with the ratio of induced lymphocytes according to Rosai's classification (p = 0.045). CONCLUSION: In thymoma, telomerase activity reflects the presence of immature T-cell lymphocytes in tumor tissue rather than tumor stage or malignant phenotype. In thymic carcinoma, telomerase activity derived directly from cancer cells may relate to tumor stage.
机译:背景:端粒酶是一种核蛋白复合物,其盖住所有真核染色体的物理末端。建议端粒酶在恶性表型的无限细胞分裂采集中起重要作用。我们研究了胸腺瘤和胸腺癌中端粒酶活性与这些病变的临床病理特征的关系。方法:组织标本从胸腺瘤和胸腺癌患者手术切除。根据改性的直接重复扩增方案(疏水阀)测定评估端粒酶活性。结果:在所有胸腺上皮肿瘤中检测到端粒酶活性。胸腺瘤(n = 17)中的活动(平均值+/-sd:单位/微克蛋白质)显着高于胸腺癌(n = 7)[431.8 +/- 400.1与68.8 +/- 39.8:p <0.01]。胸腺瘤和胸腺癌中的端粒酶活性显着高于原发性肺腺癌(33.5 +/- 39.2:n = 47),如对照研究(P <0.01)。在胸腺瘤患者中,根据Masaoka分类,端粒酶活性与肿瘤阶段没有与肿瘤阶段相关(p = 0.776)。然而,在胸腺癌患者中,端粒酶活性与肿瘤阶段正相关(P = 0.02)。在胸腺瘤中,端粒酶活性与罗伊分类的诱导淋巴细胞的比例正相关(P = 0.045)。结论:在胸腺瘤中,端粒酶活性反映肿瘤组织中未成熟的T细胞淋巴细胞的存在,而不是肿瘤阶段或恶性表型。在胸腺癌中,直接从癌细胞衍生的端粒酶活性可能与肿瘤阶段有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号